Adjusting diffusing capacity for anemia in patients undergoing allogeneic HCT: a comparison of two methodologies - 26/04/24
, Mehrdad Hefazi Torghabeh b, Sumedh S Hoskote a, Kelly M Pennington c, Kaiser G Lim a, Paul D Scanlon a, Alexander S Niven a, William J Hogan bAbstract |
Background |
Diffusing capacity (DLCO) measurements are affected by hemoglobin. Two adjustment equations are used: Cotes (recommended by ATS/ERS) and Dinakara (used in the hematopoietic stem cell transplantation comorbidity index [HCT-CI]). It is unknown how these methods compare, and which is better from a prognostication standpoint.
Study design |
This is a retrospective cohort of 1273 adult patients who underwent allogeneic HCT, completed a pre-transplant DLCO and had a concurrent hemoglobin measurement. Non-relapse mortality was measured using competing risk analysis.
Results |
Patients had normal spirometry (FEV1 99.7% [IQR: 89.4–109.8%; FVC 100.1% [IQR: 91.0-109.6%] predicted), left ventricular ejection fraction (57.2[6.7]%) and right ventricular systolic pressure (30.1[7.0] mmHg). Cotes-DLCO was 85.6% (IQR: 76.5-95.7%) and Dinakara-DLCO was 103.6% (IQR: 90.7-117.2%) predicted. For anemic patients (Hb<10g/dL), Cotes-DLCO was 84.2% (IQR: 73.9–94.1%) while Dinakara-DLCO 111.0% (97.3–124.7%) predicted. Cotes-DLCO increased HCT-CI score for 323 (25.4%) and decreased for 4 (0.3%) patients. Cotes-DLCO was superior for predicting non-relapse mortality: for both mild (66-80% predicted, HR 1.55 [95%CI: 1.26-1.92, p < 0.001]) and moderate (<65% predicted, HR 2.11 [95%CI: 1.55-2.87, p<0.001]) impairment. In contrast, for Dinakara-DLCO, only mild impairment (HR 1.69 [95%CI 1.26-2.27, p < 0.001]) was associated with lower survival while moderate impairment was not (HR 1.44 [95%CI: 0.64-3.21, p = 0.4]). In multivariable analyses, after adjusting for demographics, hematologic variables, cardiac function and FEV1, Cotes-DLCO was predictive of overall survival at 1-year (OR 0.98 [95%CI: 0.97-1.00], p = 0.01), but Dinakara-DLCO was not (OR 1.00 [95%CI: 0.98-1.00], p = 0.20).
Conclusion |
The ERS/ATS recommended Cotes method likely underestimates DLCO in patients with anemia, whereas the Dinakara (used in the HCT-CI score) overestimates DLCO. The Cotes method is superior to the Dinakara method score in predicting overall survival and relapse-free survival in patients undergoing allogeneic HCT.
Le texte complet de cet article est disponible en PDF.Keywords : Diffusing capacity, DLCO, Anemia, HCT, Bone marrow transplant
Abbreviation : ATS, ERS, DLCO, PFT, HCT, HCT-CI, RIC, FEV1, FVC, GLI, ROC, CO
Plan
Vol 72 - N° 2
Article 103432- juin 2024 Retour au numéro
Article précédent
- Performances of the H-score and the HLH-2004 score in the positive diagnosis of secondary hemophagocytic lymphohistiocytosis
- Abida Fatma, Ben Salah Raida, Chaari Mourad, Dammak Ikram, Bahloul Zouheir, Elleuch Henda
- Catechol-O-methyltransferase gene (COMT) is associated with neurocognitive functioning in patients with sickle cell disease
- Andrew M. Heitzer, Sara R. Rashkin, Ana Trpchevska, Jennifer N. Longoria, Evadnie Rampersaud, Yunusa Olufadi, Winfred C. Wang, Darcy Raches, Brian Potter, Martin H Steinberg, Allison A. King, Guolian Kang, Clifford M. Takemoto, Jane S. Hankins
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?